Kornimate/medical-research-clean huggingface dataset:
clinical practice of aecopd management in china

Conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is observe clinical practice including glucocorticoids treatment in aecopd in china.

it is widely recognized that the global social and economic burden of chronic obstructive pulmonary disease (copd) is high; affecting an estimated 64 million people worldwide. it was reported the prevalence of copd in china population over 40 years old is about 8.2% (zhong nanshan et al, 2007). according to the report on china chronic disease, copd is the second disease of disability adjusted life years. the economic burden of copd is tremendous in china. cost analysis in 2006 showed that every copd patient in urban would pay 1732.24 $ on medical cost every year, indirect cost on nurse and traffic is 231.6 $, total cost would account for 40% of average family income in 2006(chiang ch.,2008).aecopd is one of most important cause leading to copd death. corticosteroid is essential for aecopd management and recommended by domestic and international guidelines. but it shows that corticosteroid use for treating aecopd in china is around 70% from market research in big hospitals, and less report about how steroid is used for aecopd management was published, including distribution, dosage, treatment duration, etc. the healthcare resources utilization for treating aecopd in china is also unclear.

Eligibility criteria:
inclusion criteria: 1. ≥40 years old 2. hospitalization treatment due to aecopd since sep, 2013 3. diagnosed by gold 2013 as copd at least 3 months before aecopd based on treating physician's judgment 4. provided informed consent or informed consent waiver exclusion criteria: 1. participation in any interventional clinical study within 3 months before being recruited in the study. 2. ongoing aecopd during recruitment timeline 3. the patients whose symptoms haven't recovered and then discharge by themselves 4. the primary diagnosis of hospitalization is not aecopd
rfa for gim treatment

Conditions: Gastric Intestinal Metaplasia; Treatment; Radio-frequency Ablation

Summary: use radiofrequency ablation (rfa) for gastric intestinal metaplasia (gim) treatment.

gastric intestinal metaplasia (gim) is a pre-malignant lesion. currently, there is no standard treatment for this condition, thus the patients with gim need surveillance endoscopy every 1-3 years, regarding to the severity and extension of lesion. however, the protocol for gim surveillance is uncertain and need high cost. radiofrequency ablation (rfa) is used for barrett's esophagus (be; pre-malignant lesion of esophageal adenoca) treatment as a standard treatment. the investigators hypothesized that rfa may effective in gim treatment. the investigators will random gim participants to have the rfa treatment only one site of the stomach (left or right). at the first session, the investigators will biopsy at suspected gim lesions to confirm the diagnosis and severity of gim. two months later, the investigators will apply rfa to all gim lesions at the assigned location and then every 2 months for 3 sessions or until no gim lesion seen by endoscopy. the final endoscopy will be done at 1 year follow-up and biopsy will be performed to assess the efficacy of rfa compare to no treatment.

Eligibility criteria:
inclusion criteria: * more than 18 years of age * previous diagnose of extensive or incomplete gim exclusion criteria: * no gim at first endoscopy * previous gastric surgery * coagulopathy * pregnancy or lactation * unable to perform appropriate peri-procedural cessation of antiplatelet/antithrombotic therapy * unable to sign the consent
metformin versus insulin in the treatment of gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus

Summary: the purpose of this study is to determine if metformin therapy prevents fetal macrosomy in gestational diabetes mellitus to the same extent as insulin therapy.


Eligibility criteria:
inclusion criteria: * gestational diabetes mellitus diagnosed between 12-34 pregnancy weeks if normoglycemia is not reached with diet exclusion criteria: * hypertension with pharmacological treatment or preeclampsia * multiple pregnancy * liver or kidney disease

Keywords: gestational diabetes mellitus treatment metformin
study for the use of alteplase in patients who awaken with stroke

Conditions: Ischemic Stroke

Summary: this is a pilot study of thrombolytic therapy in patients with ischemic stroke who present with stroke symptoms upon awakening.

patients with ischemic stroke are currently only eligible for the treatment with intravenous thrombolysis if the stroke is diagnosed within 4.5 hours from known onset of symptoms. many patients awaken with stroke and are excluded from this therapy, following current guidelines. patients who suffer from a stroke just before or after waking up may be candidates for thrombolysis and our study will use advanced neuroimaging to select those patients.

Eligibility criteria:
inclusion criteria: 1. age ≥22 2. stroke upon awakening 3. measurable deficit by nihss 4. no deficit before sleep or last seen normal before to sleep 5. head ct with no evidence of intracranial hemorrhage. 6. able to receive iv t-pa treatment within 2.5 hrs after patient awoke with deficit. 7. written informed consent signed and dated by the patient (or patient's authorized representative) 8. core lesion: aspects ≥7 on mri-dwi, ctp-cbv or cta source imaging. 9. mismatch of at least 20% measured by ct cvb/mmt or dwi/ttp exclusion criteria: 1. stroke or serious head trauma within the preceding 3 months 2. major surgery or serious trauma within 14 days 3. history of intracranial hemorrhage 4. systolic blood pressure above 185 mm hg or diastolic blood pressure above 110 mm hg that is not controlled after aggressive measures. 5. rapidly improving or minor symptoms 6. symptoms suggestive of subarachnoid hemorrhage. 7. gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 21 days. 8. arterial puncture at a non-compressible site within the previous 7 days 9. seizure at the onset of stroke and considered the cause for the neurological symptom. 10. patients who are taking anticoagulants or who had received heparin within the 48 hours preceding the onset of stroke and have an elevated partial-thromboplastin time, inr\>1.7 or platelet counts below 100,000/mm3 11. finger sticks glucose below 50 mg/dl (2.7 mmol/ lt) or above 400 mg per deciliter (22.2 mmol/lt) and considered the cause for the neurological symptom. 12. active internal bleeding 13. pregnancy in women of child-bearing potential (must have pregnancy test, urine or blood, prior to therapy). 14. lumbar puncture within 7 days. 15. known co-morbid conditions likely to complicate therapy or interfere with patient assessment, such us: heart failure stage 4, severe dementia, end-stage aids, pericarditis, cirrhosis or known cancer. 16. unable to obtain cta or perfusion brain studies (pwi or ctp)

Keywords: stroke ischemia thrombolysis thrombolytics tpa rt-pa t-pa activase® alteplase wake-up stroke waking onset stroke sleep
pilates exercises on pain, fatigue, endurance, and muscle strength in non-specific low back pain

Conditions: Low Back Pain

Summary: pilates exercises administered under the supervision of a physiotherapist on pain, endurance, and muscle strength in individuals with non-specific low back pain, and to determine which program is more beneficial and reliable.

the aim of this study is to compare the effects of different types of pilates exercises administered under the supervision of a physiotherapist on pain, endurance, and muscle strength in individuals with non-specific low back pain, and to determine which program is more beneficial and reliable.

Eligibility criteria:
inclusion criteria * aged between 18 and 60 years * non-specific low back pain for more than 12 weeks * no clear pathological diagnosis * physically and cognitively capable of performing the exercises * pain level between 3 and 7 on the visual analog scale (vas) exclusion criteria * pregnancy * spinal surgery in the last 6 months * neurological or chronic systemic diseases * movement restriction due to severe pain

Keywords: exercise
nrs 2002: nutritional screen in cancer patients

Conditions: Malnutrition (Diagnosis); Nutrition Disorders; Nutrition Surveys; Scoring System; Cancer; Nutrition Related Cancer

Summary: diagnosing the nutritional status of cancer patients is extremely important. an appropriate nutritional status supports a better tolerance to the treatment. a working protocol is essential to start with nutritional screening. if it is detected malnutrition risk or malnutrition, diet counseling, and the specific therapeutic for each patient must be provided. this descriptive study will serve three aims: * register in the cancer patient's electronic medical record their nutritional status at the admission and when the patient is discharged. * determine the percentage of malnourished patients or in the risk of malnutrition who are admitted to hospitalization. * recognize the number of patients that required specialized nutritional care. the purpose of this study is to determine if 30% of the patients admitted to the headquarters of solca in guayaquil from the ecuadorian cancer society are at malnutrition risk or with any specific malnutrition level.

a prospective, descriptive, non-interventional study that will be performed from july 1st to october 4th of 2019 in all hospitalized patients of the internal medicine service from solca in guayaquil from the ecuadorian cancer society. statistical analysis: central tendency measures. the results will be presented with tables and graphs. two weeks before the start of the study, the training of the personnel that will intervene in the screening of the participants will be carried out and will have a flow chart of actions to follow according to the status of patients.

Eligibility criteria:
inclusion criteria: * participants older than 18-year old that go to the mentioned service exclusion criteria: * all patients with more than 48 hours of hospital admission * pediatric population. * patients with edema, non-malignant conditions (family of solca workers) or with oncologic diagnosis not confirmed * participants who use a wheelchair or stretcher and those who cannot stand up the nrs 2002 screening tool will be used to collect data and register the electronic medical record of each patient according to their nutritional status. the variables to be recorded in an online excel shared sheet (google drive) are weight, height, bmi, age, cancer diagnosis, associated comorbidities. for weight determination, a scale (mechanical or electronic) in good condition will be used

Keywords: cancer hospitalized patients nutrition disorders scoring system nutrition surveys nutrition assessment
bioenhancing effects of black pepper with turmeric on pain ratings

Conditions: Pain

Summary: although multiple clinical trials have been reported studying the effects of turmeric and turmeric-derived curcuminoid containing extract on pain by various study designs (including both acute and chronic pain), with the most consistent positive pain reduction benefits at turmeric or curcuminoid levels above normal dietary intake estimates, studies assessing the combination of black pepper and turmeric at culinary relevant levels for pain remediation benefits are needed. as black pepper is reported to 'enhance' the effects of co-consumed compounds, we are testing whether consumption of black pepper alters the pain alleviating effects of turmeric when consumed at levels representative of potential dietary intakes.


Eligibility criteria:
inclusion criteria: * age: 40 or older * bmi: 20-40 * diet: no dietary prohibitions/allergies * 21-day availability * moderate pain rating (self-reported numeric rating 4-7 on 10 pt scale) exclusion criteria: * turmeric or black pepper allergy, or any allergy that would prevent menu item selections for 7 days of feeding * recent change in pain levels - e.g. acute injury * known eating disorder * no access to a phone capable of text message, electronic device (phone, tablet, computer/laptop) with email and internet access * inability to continue on protocol for 3 consecutive weeks. * medical conditions (cardiovascular disease event within the past six months, severe pulmonary disease, renal failure, major liver dysfunction within the last 2 years, digestive disorders including gastric reflux, irritable bowel disease, crohn's disease or related conditions current smoker or recently quit less than 6 months prior) or medications that would prevent the ability to comply with treatment assignment (e.g. blood thinners, arrhythmia control medications, prescription narcotic pain medications). * use of estrogen or testosterone replacement therapy within the past 6 months, * current use of oral corticosteroids \> 5 days/month on average * cold, flu, virus, allergy or other conditions that impairs sensory perceptions (taste and smell) which may impact protocol compliance * covid19 positive status at time of enrollment * consumes an average of ≥1 serving of turmeric per day, or has never consumed and/or would not be willing to consume turmeric * consumes black pepper ≥ 3 servings per day and/or would not be willing to abstain from pepper consumption for the prescribed days during the study * abstinence from or dislike of either turmeric or black pepper * dependence on others for food procurement and preparation
application of fapi visualization in the assessment of right ventricular dysfunction due to volume overload

Conditions: Right Heart Insufficiency; Tricuspid Regurgitation

Summary: \&#34;bicuspid aortic stenosis represents the most prevalent form of cardiac valve disease, primarily resulting from degenerative alterations and rheumatic conditions that disrupt mitral valve function. this dysfunction exacerbates the hemodynamic burden on the right heart, leading to secondary pulmonary hypertension-a condition uniquely predisposed to myocardial fibrosis. the role of right ventricular (rv) fibrosis in pulmonary hypertension induced by bicuspid aortic stenosis remains an area of active investigation. modifications in the extracellular matrix collagen network may mitigate excessive dilation of the pressure-overloaded right ventricle; however, fibrosis concurrently compromises cardiac performance. an increasing body of experimental evidence indicates that fibrosis is pivotal in both the onset and progression of right ventricular dysfunction. in cases of secondary pulmonary hypertension, the right ventricle endures a posterior load approximately five times greater than normal, rendering these circumstances an excellent model for examining pressure loading effects on rv structure. notably, severe rv fibrosis persists even after hemodynamic normalization following mitral valve repair; thus, preoperative evaluation of rv fibrosis is essential for optimizing patient outcomes in individuals with secondary pulmonary hypertension attributable to bicuspid aortic stenosis. in recent years, myocardial nuclear imaging has gained prominence as a tool for assessing myocardial fibrosis. initial studies investigated fapi myocardial nuclear imaging\&#39;s efficacy in evaluating left ventricular fibrosis among patients with aortic stenosis; subsequent research elucidated its correlation with sudden cardiac death risk in individuals suffering from obstructive hypertrophic cardiomyopathy. the comprehension regarding how myocardial fibrosis impacts right ventricular function within patients experiencing pulmonary hypertension due to bicuspid aortic stenosis remains limited. the association between histological rv fibrosis and adverse prognostic indicators as well as outcomes related to right heart failure warrants further exploration.\&#34;


Eligibility criteria:
inclusion criteria: clinical diagnosis of tricuspid valve insufficiency; must understand the purpose of the study and signed an informed consent form; exclusion criteria: combined coronary artery stenosis; combined with aortic aneurysm related diseases; patients with congenital heart disease;
10-year follow-up of a wide diameter bone anchored hearing implant

Conditions: Hearing Loss

Summary: a single centre, open, comparative, parallel group, prospective clinical investigation with a single 10 year follow up visit.

this study is a continuation of two previous conducted trials: 1. stability, long term survival and tolerability of a novel baha® implant system, a multi-centre investigation new bia300 (test) implant vs previous generation (control) implant: 1. cag5173: 6-month(1) and 3-year(2) data. 2. cbas5562: 5-year data(3). 2. 3 weeks loading: stability, long term survival and tolerability of a novel baha® implant system, a multi-centre investigation 3 week loading vs 6+ week loading (= same group as control group trial 1). 6- month(4) and 3-year(5) data. in this study the (5-year data for trial 2 and) 10-year data regarding stability, survival and soft tissue tolerability from the above mentioned trials will be evaluated and compared. the previous trials were multicentre, but the current study will be single-centred and therefore only include the participants of the radboud site. data will be collected at a visit at (5 years, for trial 2 and) 10 years (+/- 6 months) after implantation. up to now, no rct of these implants (with the loading of 3 weeks after implantation) has assessed stability, survival and tolerability over a 10-year follow-up period.

Eligibility criteria:
inclusion criteria: * to be included in the original trials, patients had to be at least 18 years old. exclusion criteria: * exclusion criteria were an inability to follow investigational procedures, any factor at the discretion of the investigator that was considered to contraindicate participation, and any disease or treatment known to compromise the bone quality at the implant site. for patients who had lost or removed the implant, the time to implant loss was recorded. patients who could not attend the 5 or 10 year follow-up visit for other reasons were included in the implant survival analysis as well; the last available information regarding implant survival was obtained verbally from the patient, from medical records, or from information captured from the original investigations. furthermore, patients were excluded if they had a bone thickness less than 4 mm at the implant site during implantation.
thalidomide low threshold in epilepsy

Conditions: Refractory Epilepsy

Summary: the purpose of this study is to determine whether thalidomide is effective in the refractory epilepsy treatment.

seven male patients with chronic, refractory epilepsy were included in the present study; in all cases antiepileptic treatment with multiple antiepileptic drugs had been unsuccessful in reducing the frequency or the intensity of seizures. patients selected for this study were all males due to the high risk of thalidomide for teratogenicity in pregnant women; besides this drawback, thalidomide presents a fair tolerance profile in humans treated with low doses. informed consent was obtained on each case by the patient and his legal guardian. the protocol was approved by the committees of research and ethics. treatment with thalidomide at 200 mg dosage twice daily was administered during a twelve month period. electroencephalograms were obtained prior and at six months of thalidomide therapy; number and intensity of seizures were individually recorded in a diary by a caregiver (in most cases the patient's mother); signs of neuropathy, a frequent side-effect of chronic thalidomide therapy, were evaluated along the treatment; drowsiness and sedation, which are also common side-effects, were also recorded. patients were seen once a week during the treatment period at the epilepsy clinic of the national institute of neurology and neurosurgery of mexico. once informed consent was obtained, all patients were given seizure diaries to be filled for three months before starting the treatment with thalidomide. comparisons in the frequency of seizures were made on each patient by contrasting the three months previous to the beginning of thalidomide therapy with the twelve months of the drug trial. one patient (case 6) withdrew from the trial after seven months of thalidomide therapy due to sedation. another patient (case 7) withdrew from the trial after 3 months of treatment due to exacerbation of seizures as narrated by his mother. the same schedule of antiepileptic therapy was taken by each patient during three months prior to thalidomide administration and continued it without modification along the trial; therefore, bias due to changes in the associated antiepileptic medications were prevented and each patient served as his own control; so that the effect of thalidomide on the frequency and intensity of seizures could be reasonably evaluated. thalidomide was purchased by the national institute of neurology and neurosurgery of mexico at regular price in the pharmaceutical market. no pharmaceutical company participated in any form in this trial.

Eligibility criteria:
inclusion criteria: * refractory epilepsy, males exclusion criteria: * females, peripheric neuropathy

Keywords: thalidomide antiepileptic drugs refractory epilepsy sedative drugs